An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Spectrum Pharmaceuticals announced an oral presentation on poziotinib at the ESMO Targeted Anticancer Therapies Congress 2022, scheduled for March 7-8, 2022. The presentation will discuss the efficacy and safety of poziotinib in treating HER2 exon 20 insertion mutated non-small cell lung cancer. Dr. Sophie Sun will present findings during a mini oral session on March 7, 2022, at 5:50 p.m. CET. Attendees can access the presentation online post-event on the ESMO website and Spectrum's official site.
Positive
Presentation on poziotinib at a significant oncology congress may enhance visibility and credibility.
Focus on novel therapies aligns with unmet medical needs in oncology, potentially driving future growth.
Negative
Dependence on FDA and regulatory approval processes presents uncertainty in drug commercialization.
Risks associated with new drug candidates not proving effective or safe could impact future prospects.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2022 being held virtually March 7-8, 2022. Details of the presentation are as follows:
Title: Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Speaker: Sophie Sun, M.D., FRCPC
Session Type: Mini oral session
Date and Time: March 7, 2022 at 5:50 p.m. CET / 11:50 a.m. ET Presentation Number: 26MO
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
